“Volpara’s vendor neutral stance and scientifically proven capability to measure breast density is the key for adoption across whole breast screening programs,” said Ralph Highnam, CEO of Matakina International Ltd.
WELLINGTON, New Zealand (PRWEB) April 24, 2012
Matakina International Limited of Wellington, New Zealand, today announced that it has signed a distribution agreement with Commit Oy of Finland to distribute Volpara to their customer base. The Volpara breast density software works on images from most x-ray vendors and is CE marked and FDA cleared.
“Volpara’s vendor neutral stance and scientifically proven capability to measure breast density is the key for adoption across whole breast screening programs,” said Ralph Highnam, CEO of Matakina International Ltd. “Inking this deal with Commit allows one of the most pre-eminent healthcare companies in Finland to give Finnish women the opportunity to start receiving this important breast health information.”
“Commit sees that it is vital to the success in this demanding field to increase quality of work in both image acquisition and also in reading of breast images. Whereas our products to date focus on improving productivity, we are increasingly looking for dedicated tools to increase clinical impact in the overall process,” says Markku Myllylä, CEO of Commit; Oy.
Breast tissue density has not only been linked to an increased risk of breast cancer, it also decreases the sensitivity of the mammogram and thereby may impact early detection. Several large studies have confirmed that as tissue density increases, the accuracy of mammography decreases. Thirty-five percent of breast cancer goes undetected by mammography in women with dense breasts, as density masks the appearance of tumors (Boyd et al 2007, NEJM). Since both dense breast tissue and cancer appear white on a mammogram, finding cancers can be analogous to looking for a snowball in a snow storm.
Volpara provides radiologists a reliable tool to automatically generate objective volumetric breast density values, the FDA-cleared Volpara breast imaging software computes volumetric breast tissue density from digital mammograms. Volpara software assists radiologists by providing an objective, automatic measurement of volumetric breast tissue density and provides the Volpara Density Grade that is correlated with the American College of Radiology BIRADS Density Grading Classifications. Volpara integrations with other digital mammography systems, CAD systems and mammography reporting system are also underway.
Founded to enable radiologists to give women the most accurate information possible regarding their breast health, Matakina International, Limited is the wholly owned sales and marketing arm of Matakina Technology Limited of New Zealand. Volpara’s founders and Board of Directors includes John Hood, PhD, former Vice Chancellor of the University of Oxford, UK, Ralph Highnam, PhD, former CEO of Mirada Solutions, one of the University of Oxford’s most successful spin-outs of recent times and co-author of the seminal book Mammographic Image Analysis; and Professor Sir Michael Brady, a serial entrepreneur who recently retired from the University of Oxford where he was Professor of Information Technology for 25 years.
Commit is a major provider of solutions for radiology departments in Finland. Commit has since 1996 implemented digital imaging archive and digital work flow systems for the Finnish customer base, both in private and public sectors. Commit product line includes a fully automated, comprehensive product for breast cancer screening programmes, a product called Commit; Screening MIS.
# # #
Chris K. Joseph